Non-Postoperative Acute Pain Treatment Market to Exhibit Enormous Growth During the Study Period (2019-2032) | DelveInsight
The landscape of the non-postoperative acute pain market is expected to transform in the upcoming years due to the projected introduction of new therapies, heightened awareness of related illnesses, a rise in global healthcare expenditure, and an uptick in research and development efforts, among other factors.
LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.
Key Takeaways from the Non-Postoperative Acute Pain Market Report
- According to DelveInsight's analysis, the market size for non-postoperative acute pain reached USD 3 billion in 2022 across the US and is expected to grow with a significant CAGR by 2032.
- DelveInsight's analysis reveals that the overall incident population of non-postoperative acute pain in the US was reported as ~53 million in 2022.
- In the United States, about 50% of the individuals diagnosed with non-postoperative acute pain experienced a moderate level of severity.
- Leading non-postoperative acute pain companies such as Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others are developing novel non-postoperative acute pain drugs that can be available in the non-postoperative acute pain market in the coming years.
- The promising non-postoperative acute pain therapies in the pipeline include VX-548, Eptinezumab, STS101 (DHE Nasal Powder), AXS-07, Naltrexone-Acetaminophen, and others.
Discover which therapies are expected to grab the major non-postoperative acute pain market share @ Non-Postoperative Acute Pain Market Report
Non-Postoperative Acute Pain Overview
Non-postoperative acute pain pertains to immediate discomfort stemming from various origins unrelated to surgical interventions. It can arise from diverse factors such as injuries, illnesses, trauma, burns, cuts, infections, or tissue damage. The pain may manifest in different areas of the body, necessitating a systematic diagnostic strategy that encompasses patient history, physical examination, and, if deemed essential, imaging or laboratory tests. The objective is to pinpoint the origin and characteristics of the pain to devise a customized treatment plan. Managing non-surgical acute pain may involve the use of analgesic medications, implementation of physical therapy, and addressing the underlying medical condition. A holistic, multidisciplinary approach is frequently indispensable to ensure thorough care and efficient alleviation of pain for individuals undergoing non-surgical acute pain.
Non-Postoperative Acute Pain Epidemiology Segmentation
The non-postoperative acute pain epidemiology section provides insights into the historical and current non-postoperative acute pain patient pool and forecasted trends for the US. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The non-postoperative acute pain market report proffers epidemiological analysis for the study period 2019–2032 in the US segmented into:
- Total Diagnosed Incident Cases of Non-Postoperative Acute Pain
- Type-specific Cases of Non-Postoperative Acute Pain
- Severity-specific Cases of Non-Postoperative Acute Pain
- Total Treated Cases of Non-Postoperative Acute Pain
Non-Postoperative Acute Pain Treatment Market
Acute pain arises from various sources such as injury, surgery, illness, trauma, or painful medical procedures, acting as a signal for underlying health issues or bodily threats. Typically, it is short-lived and diminishes once the root cause is addressed or healed. Achieving optimal pain relief requires a multimodal treatment approach, which is essential in minimizing side effects by combining different methods. Key components of this approach include nerve blocks or epidurals, opioids or alternative analgesics, supplementary medications, physical modalities like RICE (rest, ice, compression, elevation), and rehabilitation. Additionally, psychosocial interventions such as distraction, meditation, and deep breathing play integral roles.
The current non-postoperative acute pain treatment strategy encompasses a variety of approaches categorized into pharmacologic and nonpharmacological therapies. In today's non-postoperative acute pain treatment market, options like opioids, NSAIDs, and other anesthetics are available. The efficacy of pain relief is paramount, especially in the context of patients undergoing surgery. Consequently, there is anticipation within the pain market for innovative therapies that significantly contribute to alleviating pain.
To know more about non-postoperative acute pain treatment guidelines, visit @ Non-Postoperative Acute Pain Management
Non-Postoperative Acute Pain Pipeline Therapies and Key Companies
- VX-548: Vertex Pharmaceuticals
- Eptinezumab: H. Lundbeck A/S
- STS101 (DHE Nasal Powder): Satsuma Pharmaceuticals
- AXS-07: Axsome Therapeutics
- Naltrexone-Acetaminophen: Allodynic Therapeutics
Learn more about the FDA-approved drugs for non-postoperative acute pain @ Drugs for Non-Postoperative Acute Pain Treatment
Non-Postoperative Acute Pain Market Dynamics
The dynamics of the non-postoperative acute pain market are expected to change in the coming years. As awareness around pain management increases, there is a growing demand for innovative solutions that extend beyond the realm of postoperative care. The non-postoperative acute pain market is witnessing a shift towards a more patient-centric approach, with an emphasis on personalized and multimodal pain management strategies. Additionally, the pharmaceutical sector is responding with the development of novel analgesics that aim to balance efficacy with reduced side effects, addressing concerns surrounding opioid use.
Furthermore, many potential therapies are being investigated for the treatment of non-postoperative acute pain, and it is safe to predict that the treatment space will significantly impact the non-postoperative acute pain market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the non-postoperative acute pain market in the 7MM.
However several factors may impede the growth of the non-postoperative acute pain market. One key obstacle is the complexity of pain itself, as it often arises from diverse sources and manifests differently among individuals. This diversity makes it challenging to create universal treatments that cater to the varying nature of non-postoperative acute pain.
Moreover, non-postoperative acute pain treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the non-postoperative acute pain market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the non-postoperative acute pain market growth.
Non-Postoperative Acute Pain Market Report Metrics | Details |
Study Period | 2019–2032 |
Coverage | The United States |
Non-Postoperative Acute Pain Market Size in 2022 | USD 3 Billion |
Key Non-Postoperative Acute Pain Companies | Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others |
Key Pipeline Non-Postoperative Acute Pain Therapies | VX-548, Eptinezumab, STS101 (DHE Nasal Powder), AXS-07, Naltrexone-Acetaminophen, and others |
Scope of the Non-Postoperative Acute Pain Market Report
- Therapeutic Assessment: Non-Postoperative Acute Pain current marketed and emerging therapies
- Non-Postoperative Acute Pain Market Dynamics: Key Market Forecast Assumptions of Emerging Non-Postoperative Acute Pain Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Non-Postoperative Acute Pain Market Access and Reimbursement
Discover more about non-postoperative acute pain drugs in development @ Non-Postoperative Acute Pain Clinical Trials
Table of Contents
1. | Non-Postoperative Acute Pain Key Insights |
2. | Non-Postoperative Acute Pain Report Introduction |
3. | Non-Postoperative Acute Pain Overview at a Glance |
4. | Non-Postoperative Acute Pain Executive Summary |
5 | Non-Postoperative Acute Pain Key Events |
6 | Epidemiology and Market Forecast Methodology |
6. | Disease Background and Overview |
7. | Non-Postoperative Acute Pain Treatment and Management |
8. | Non-Postoperative Acute Pain Guidelines |
9. | Non-Postoperative Acute Pain Epidemiology and Patient Population |
10. | Patient Journey |
11. | Key Endpoints in Non-Postoperative Acute Pain |
12. | Non-Postoperative Acute Pain Marketed Drugs |
13. | Non-Postoperative Acute Pain Emerging Drugs |
14. | US Non-Postoperative Acute Pain Market Analysis |
15. | Market Access and Reimbursement |
16. | KOL Views |
17. | Unmet Needs |
18. | SWOT Analysis |
19. | Appendix |
20. | DelveInsight Capabilities |
21. | Disclaimer |
22. | About DelveInsight |
Related Reports
Postoperative Pain Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key postoperative pain companies, including Concentric Analgesics, Oculis Pharma, Vivozon Pharmaceutical Inc., Haisco Pharmaceutical Group, Jiangsu HengRui Medicine Co., Ltd., Nevakar, Inc., Flexion Therapeutics, LipoCure, SiteOne Therapeutics, Allay Therapeutics, Bexson Biomedical, InSitu Biologics, among others.
Postoperative Pain Epidemiology Forecast
Postoperative Pain Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted postoperative pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Postoperative Pain Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key postoperative pain companies, including Taiwan Liposome Company (TLC), Teikoku Pharma USA, Novartis Pharmaceuticals, Concentric Analgesics, Mati Therapeutics, Arthritis Innovation Corporation, MedinCell, Surface Ophthalmics, Salvat Laboratories, Grünenthal, Vertex Pharmaceuticals, Formosa Pharmaceuticals, Oculis, Neumentum Pharmaceuticals, Charleston Laboratories, among others.
Acute Pain Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute pain companies, including Hyloris Pharmaceuticals, AFT Pharmaceuticals, Formosa Pharmaceuticals, Concentric Analgesics, Vivozon, Vertex Pharmaceuticals, Taiwan Liposome Company (TLC), Medical Developments International (MVP), Neumentum Pharmaceuticals, Charleston Laboratories, AcelRx Pharmaceuticals, Teikoku Pharma USA, PainReform, Nevakar, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
+91-9650213330
Logo - https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
Share this article